Researchers have succeeded in developing an E. coli-based ‘smart microbe’ that secretes therapeutic payloads, including antibodies, into the gut. The genetically modified beneficial strain of bacteria blocks intestinal inflammation in a preclinical model of inflammatory bowel disease and has the potential to treat intestinal-based diseases.